Table of Contents
Issues in the Clinical Development of Investigational Agents Being Evaluated for the Post-surgical Adjuvant Treatment of High-Risk (Stage IIb and III) Melanoma
Adjuvant Treatment for Malignant Melanoma Outline of Presentation
Adjuvant Treatment for Malignant Melanoma Outline of Presentation Invited Speakers
Adjuvant Treatment for Malignant Melanoma Regulatory considerations
Adjuvant Treatment for Malignant Melanoma Evolution in Regulatory Approach
Adjuvant Treatment for Malignant Melanoma Evolution in Regulatory Approach
Adjuvant Treatment for Malignant Melanoma
Adjuvant Treatment for Malignant Melanoma Survey Approach
Adjuvant Treatment for Malignant Melanoma Number of INDs for the Treatment of Melanoma
Adjuvant Treatment for Malignant Melanoma Number of Studies and Subjects Accrued by Phase of Study
Adjuvant Treatment for Malignant Melanoma Investigational Products
Adjuvant Treatment for Malignant Melanoma Investigational Products
Adjuvant Treatment for Malignant Melanoma Investigational Products
Adjuvant Treatment for Malignant Melanoma
Adjuvant Treatment for Malignant Melanoma Study ECOG 1684
Adjuvant Treatment for Malignant Melanoma Study ECOG 1684
Adjuvant Treatment for Malignant Melanoma Study ECOG 1684
Adjuvant Treatment for Malignant Melanoma K-M estimates of DFS ECOG 1684 (from the published report)
Adjuvant Treatment for Malignant Melanoma K-M estimates of OS ECOG 1684 (from the published report)
Adjuvant Treatment for Malignant Melanoma Labeled Indication
Adjuvant Treatment for Malignant Melanoma Study ECOG 1690
Adjuvant Treatment for Malignant Melanoma K-M estimates of DFS ECOG 1690 (from the published report)
Adjuvant Treatment for Malignant Melanoma K-M estimates of OS ECOG 1690 (from the published report)
Adjuvant Treatment for Malignant Melanoma K-M Estimates of 3-year RFS and OS Studies E 1684 and E1690 (high dose)
Adjuvant Treatment for Malignant Melanoma Interferon a 2b Adverse Events
Adjuvant Treatment for Malignant Melanoma Interferon a 2b Adverse Events
Adjuvant Treatment for Malignant Melanoma Use of INTRON-A in high risk melanoma Estimates for 2001
Adjuvant Treatment for Malignant Melanoma
Adjuvant Treatment for Malignant Melanoma Criteria for Inclusion
Adjuvant Treatment for Malignant Melanoma Search Methodology
Adjuvant Treatment for Malignant Melanoma Analytic Approach
Adjuvant Treatment for Malignant Melanoma INTRON-A High Dose
Adjuvant Treatment for Malignant Melanoma K-M estimates of DFS and OS ECOG 1694 (from the published report)
Adjuvant Treatment for Malignant Melanoma INTRON-A Low Dose
Adjuvant Treatment for Malignant Melanoma Rusciani et al. 1997 (from the published report)
Adjuvant Treatment for Malignant Melanoma K-M estimate of DFS and OS Scottish Melanoma Group (from the published report)
Adjuvant Treatment for Malignant Melanoma ROFERON-A High Dose and Low Dose
Adjuvant Treatment for Malignant Melanoma K-M estimate of DFS and OS NCCTG 83-7052 (from the published report)
Adjuvant Treatment for Malignant Melanoma K-M estimate of DFS WHO CT 16 (from the published report)
Adjuvant Treatment for Malignant Melanoma K-M estimate of DFS M 23031 (from the published report)
Adjuvant Treatment for Malignant Melanoma K-M estimate of DFS Austrian Melanoma Cooperative Group (from the published report)
PPT Slide
Adjuvant Treatment for Malignant Melanoma Odds Ratio for Survival
Adjuvant Treatment for Malignant Melanoma Wheatley et. al. Meta-Analysis
Adjuvant Treatment for Malignant Melanoma Overview by FDA and Wheatley
Adjuvant Treatment for Malignant Melanoma Overview
Adjuvant Treatment for Malignant Melanoma Summary
Adjuvant Treatment for Malignant Melanoma Effect Size Adjuvant Treatment Relative Reduction in the Odds of Recurrence and Death
PPT Slide
Adjuvant Treatment for Malignant Melanoma K-M estimates of DFS ECOG 1694 (from the published report)
Adjuvant Treatment for Malignant Melanoma K-M estimates of OS ECOG 1694 (from the published report)
Adjuvant Treatment for Malignant Melanoma K-M estimate of DFS Scottish Melanoma Group (from the published report)
Adjuvant Treatment for Malignant Melanoma K-M estimate of OS Scottish Melanoma Group (from the published report)
Adjuvant Treatment for Malignant Melanoma K-M estimate of DFS WHO CT 16 (from the published report)
Adjuvant Treatment for Malignant Melanoma K-M estimate of OS WHO CT 16 (from the published report)
Adjuvant Treatment for Malignant Melanoma K-M estimate of DFS M 23031 (from the published report)
Adjuvant Treatment for Malignant Melanoma K-M estimate of OS M 23031 (from the published report)
Adjuvant Treatment for Malignant Melanoma K-M estimate of DFS NCCTG 83-7052 (from the published report)
Adjuvant Treatment for Malignant Melanoma K-M estimate of OS NCCTG 83-7052 (from the published report)
Adjuvant Treatment for Malignant Melanoma K-M estimate of DFS M 23031 (from the published report)
Adjuvant Treatment for Malignant Melanoma Colon Cancer 5-FU levamisole
Adjuvant Treatment for Malignant Melanoma Colon Cancer 5-FU levamisole
Adjuvant Treatment for Malignant Melanoma Colon Cancer 5-FU levamisole
Adjuvant Treatment for Malignant Melanoma Colon Cancer 5-FU levamisole
Adjuvant Treatment for Malignant Melanoma Colon Cancer 5-FU levamisole
Adjuvant Treatment for Malignant Melanoma Breast Cancer Taxol
Adjuvant Treatment for Malignant Melanoma Breast Cancer Tamoxifen
Adjuvant Treatment for Malignant Melanoma K-M estimates of DFS ECOG 1684 (from the published report)
Adjuvant Treatment for Malignant Melanoma K-M estimates of OS ECOG 1684 (from the published report)
Adjuvant Treatment for Malignant Melanoma K-M estimates of DFS ECOG 1690 (from the published report)
Adjuvant Treatment for Malignant Melanoma K-M estimates of OS ECOG 1690 (from the published report)
PPT Slide
Adjuvant Treatment for Malignant Melanoma INTRON-A High Dose Results
Adjuvant Treatment for Malignant Melanoma INTRON-A Low Dose Results
Adjuvant Treatment for Malignant Melanoma ROFERON-A High Dose and Low Dose Results
Adjuvant Treatment for Malignant Melanoma Odds Ratio for Survival
Adjuvant Treatment for Malignant Melanoma Overview by FDA and Wheatley
Adjuvant Treatment for Malignant Melanoma Odds Ratio for Relapse
|